Core Viewpoint - Xtant Medical Holdings, Inc. has launched OsteoFactor Pro™, a new allogeneic growth factor solution aimed at enhancing bone healing and supporting surgical success in orthopedic and spine procedures [1][4]. Product Overview - OsteoFactor Pro™ is a naturally derived formulation rich in growth factors that enhances the biological activity and regenerative potential of orthobiologic scaffolds [2]. - The product features a biphasic release profile, providing an immediate bolus followed by sustained growth factor release, which stimulates key natural bone regeneration pathways such as angiogenesis, chemotaxis, and osteogenesis [2]. - It is an off-the-shelf, ready-to-use solution that integrates with various scaffolds, offering surgeons versatility and biologic performance for diverse bone regeneration approaches [3]. Company Positioning - With the launch of OsteoFactor Pro™, Xtant Medical becomes the first vertically integrated company to provide solutions across all five major orthobiologic categories, including demineralized bone matrix, cellular allografts, synthetics, structural allografts, and growth factors [5]. - The company emphasizes its commitment to innovation, scalability, and addressing the full spectrum of needs in regenerative medicine [5]. Company Mission - Xtant Medical's mission focuses on honoring the gift of donation to enhance patients' quality of life through a comprehensive portfolio of orthobiologics and spinal implant systems [6].

Registration Statement No. 333-276771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on February 23, 2024 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 42-1743430 (I.R.S. Employer ...

As filed with the Securities and Exchange Commission on January 30, 2024 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER (Primary Standard Industrial Classification Code Number) THE SECURITIES ACT OF 1933 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 2834 42-1743430 (I.R.S. Employer Identification Number) 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 (781) 552 ...

As filed with the Securities and Exchange Commission on May 1, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 42-1743430 (I.R.S. Employer Identification Number) 2 Burlin ...